INSYS Therapeutics, Inc. [NASDAQ:INSY]: Analyst Rating and Earnings

Equities traders often pay a significant amount of attention to what top market analysts have to say about a potential stock investment. In regards to INSYS Therapeutics, Inc. [INSY], the most recent average analyst recommendation we can read comes from the fiscal quarter ending in December. On average, stock market experts give INSY an Outperform rating. Its stock price has been found in the range of 54.74 to 86.84. This is compared to its latest closing price of $4.39.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for INSYS Therapeutics, Inc. [INSY] is sitting at 2.00. This is compared to 1 month ago, when its average rating was 2.00.

For the quarter ending in Sep-18 INSYS Therapeutics, Inc. [INSY] generated $0.02 billion in sales. That’s 22.00% lower than the average estimate of $0.02 billion as provided by Wall Street analysts. The three indicators above suggest that on the whole, this stock is not presenting an attractive investment option, as there are too many red flags that don’t point to a high-value ROI.

Keep your eyes on this company’s next financial results, which are scheduled to be made public on Thu 14 Mar (In 30 Days).

Fundamental Analysis of INSYS Therapeutics, Inc. [INSY]

This company’s Return on Total Capital is -39.37, and its Return on Invested Capital has reached -335.90%. Its Return on Equity is -101.95, and its Return on Assets is -34.26. These metrics suggest that this INSYS Therapeutics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, INSYS Therapeutics, Inc. [INSY] has generated a Total Debt to Total Equity ratio of 342.53. Similarly, its Total Debt to Total Capital is 77.40, while its Total Debt to Total Assets stands at 69.25. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 0.07, and its Long-Term Debt to Total Capital is 0.02. This company has a healthy balance between its debt and its current holdings, suggesting it is a reliable investment due to its ability to leverage debt in an efficient way.

What about valuation? This company’s Enterprise Value to EBITDA is -0.69. Total Debt to Enterprise Value stands at 4.29. INSYS Therapeutics, Inc. [INSY] has a Price to Book Ratio of 2.02.

This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 1.20 and its Current Ratio is 1.20. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Performance Indicators

Let’s now turn our attention to trading performance: INSYS Therapeutics, Inc. [INSY] has 69.21M shares outstanding, amounting to a total market cap of $303.83M. Its stock price has been found in the range of 3.35 to 11.65. At its current price, it has moved by -60.17% from its 52-week high, and it has moved 38.51% from its 52-week low.

This stock’s Beta value is currently 2.24, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 58.53. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is INSYS Therapeutics, Inc. [INSY] a Reliable Buy?

INSYS Therapeutics, Inc. [INSY] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.